PointEast Pharma Consulting, Inc. v. Lenzing Aktiengesellschaft

Full title: POINTEAST PHARMA CONSULTING, INC. v. LINZING AKTIENGESELLSCHAFT, et al

Court: United States District Court, Southern District of Texas

Date published: Sep 21, 2022

Civil Action H: 21-3654 (S.D. Tex. Sep. 21, 2022)

Opinion

Civil Action H: 21-3654

09-21-2022

POINTEAST PHARMA CONSULTING, INC. v. LINZING AKTIENGESELLSCHAFT, et al

ANDREW S. HANEN UNITED STATES DISTRICT JUDGE

ORDER ADOPTING MEMORANDUM AND RECOMMENDATION

ANDREW S. HANEN UNITED STATES DISTRICT JUDGE

Pending before the Court in the above referenced proceeding is Defendant's Motion for to Dismiss (Doc. No. 2); Defendant's Motion to Strike Plaintiffs Exhibits (Doc. No. 12); Judge Sheldon's Memorandum and Recommendation (Doc. No. 37) that the Court deny both of Defendant's motions; Defendant's Objections (Doc. No. 38); and Plaintiffs Responses to Defendant's Objections (Doc. No. 41) to the Memorandum and Recommendation.

The Court has carefully reviewed, de novo, the filings, the applicable law, the Magistrate' Judge's Memorandum and Recommendation, and the objections thereto, and agrees with the Magistrate Judge's conclusion that the Motion to Dismiss and Motion to Strike be denied. Accordingly, it is hereby

ORDERED that Defendant's Objections (Doc. No. 38) are OVERRULED; the Memorandum and Recommendation (Doc. No. 37) is ADOPTED; and Defendant's Motion to Dismiss (Doc. No. 2) and Defendant's Motion to Strike Plaintiffs Exhibits (Doc. No. 12) are both DENIED. .